Pharmaceutical Technology

JUNE 7, 2023

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98

Leads Marketing FDA Sales 98

pharmaphorum

JANUARY 19, 2023

per share deal includes $8 per share upfront, worth around $576 million, with the remainder in the form of a contingent value right (CVR) that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5

Pharma 83

Pharma Marketing FDA Leads 83

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.

Sales 52

Sales FDA Pharma Competition 52

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA 52

FDA Pharma Marketing Competition 52

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.

Government 52

Government Healthcare Healthcare Pharma 52

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Medicine 91

Medicine Healthcare Healthcare Pharma 91

Medico Reach

FEBRUARY 8, 2023

from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. from 2023 to 2030. Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors. Poised to grow at a CAGR of 29.4% The global pharmacovigilance (PV) market stood at USD 7.80

Pharma 52

Pharma Medicine Marketing Prospecting 52

Pharmaceutical Technology

NOVEMBER 23, 2022

Lifted by increased interest after the onset of the Covid-19 pandemic, the sector is expected to balloon to US$853 billion by 2030. The US still dominates the biopharma sector with more than $378bn in annual drug sales and an approximate capacity of 30% of global manufacturing. City Competitiveness Index. ft2 in Toronto 1.

Marketing 52

Marketing Manufacturing Transportation Government 52

Healthcare Success

NOVEMBER 14, 2022

billion in 2030 ). A buyer persona is a semi-fictional representation of your ideal customer based on sales data and industry research. Differentiating medical devices can be challenging due to commoditization and the fast pace of technological advances, but it’s critical to stand out in a competitive device market.

Medical 70

Medical Marketing Engineering Doctors 70

Clarivate

DECEMBER 14, 2023

With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. The arrival of a second drug may drive PBMs to expand coverage in exchange for aggressive rebates.

Marketing 52

Marketing Healthcare Healthcare Insurance 52